Nextcure Inc's Comment on Sales, Marketing and Customers
Customers who bill federal healthcare programs for products include research institutions and healthcare providers who may prescribe these products once commercialized. These customers are subject to regulatory frameworks such as the federal Anti-Kickback Statute, the False Claims Act (FCA), the Health Insurance Portability and Accountability Act (HIPAA), the Health Information Technology for Economic and Clinical Health (HITECH) Act, as well as related state and local laws. These laws impose requirements and penalties concerning fraud, privacy, security, and the transmission of individually identifiable health information. Enforcement actions by the Department of Health and Human Services Office for Civil Rights (OCR) have increased, particularly in relation to compliance with HIPAA security regulations.
In an era where the incessant pursuit of medical innovation remains paramount, NextCure, Inc. (Nasdaq: NXTC) has emerged as a prominent player in the biopharmaceutical landscape, particularly within the realm of oncology. On 7 November 2024, the company disseminated a significant business update alongside its financial results for the third quarter of 2024, reflecting both its ongoing commitment to pioneering therapies and its robust operational progress.Situated in the burgeoning field of clinical-stage biopharmaceuticals, NextCure is dedicated to the discovery and development of novel, first-in-class, and best-in-class therapeutics targeting various malignancies. Such an ambitious mandate necessitates a mu...
In a significant stride towards revolutionizing cancer treatment, NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, presented compelling preclinical and clinical data at recent prestigious meetings, including the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting. This unveiling reflects the company s unwavering commitment to developing novel therapeutic strategies that address the unmet needs in oncology.At the SITC Annual Meeting held in November 2024, NextCure showcased preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) developed in collaboration with LigaChem Biosciences. This ADC...
Forging New Frontiers in Cancer Therapy: NextCure Unveils Promising Phase 1b Study Results at ESMO 2024 BELTSVILLE, Md. Sept. 16, 2024 In a stirring presentation, NextCure, Inc. (Nasdaq: NXTC) revealed groundbreaking clinical data at the European Society for Medical Oncology (ESMO) 2024 Congress. This clinical-stage biopharmaceutical company, steadfast in its mission to revolutionize cancer treatment, shared promising results from the Phase 1b portion of a compelling Phase 1b/2 study. This pivotal research evaluates NC410, a LAIR-2 fusion protein, in combination with the immunotherapy drug pembrolizumab, targeting ovarian cancer and difficult-to-treat microsatellite stable (MSS) and microsatellite instab...
BELTSVILLE, Md., May 30, 2024 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on developing pioneering immunotherapies to treat cancer and other immune-related diseases, disclosed recent findings from their Phase 1b clinical trial combining NC410, a LAIR-2 fusion protein, with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study and Clinical FindingsThe Phase 1b portion of the Phase 1b/2 study evaluated the combination s effectiveness in patients with immune checkpoint inhibitor (ICI)-naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer conditions...
NextCure, a clinical-stage biopharmaceutical company dedicated to pioneering novel immunomedicines to combat cancer and immune-related diseases, continues to push the boundaries of scientific research. Recently, NextCure presented preclinical data at the AACR 2024 on their B7-H4 Antibody Drug Conjugate, LNCB74, showcasing its exceptional safety and pharmacokinetic profiles. This development ushers in a new era of hope for patients battling cancer.The poster presentation regarding LNCB74 presented solid evidence of its safety attributes, addressing an important concern when it comes to the development of potential therapeutics. Furthermore, highlighting its robust pharmacokinetic profiles underscores the pote...
In a groundbreaking move, NextCure, Inc. has recently published a preclinical study in the esteemed journal Science Advances, shedding light on the role of Fibronectin Leucin...
Nextcure Inc’s Comment on Sales, Marketing and Customers
Customers who bill federal healthcare programs for products include research institutions and healthcare providers who may prescribe these products once commercialized. These customers are subject to regulatory frameworks such as the federal Anti-Kickback Statute, the False Claims Act (FCA), the Health Insurance Portability and Accountability Act (HIPAA), the Health Information Technology for Economic and Clinical Health (HITECH) Act, as well as related state and local laws. These laws impose requirements and penalties concerning fraud, privacy, security, and the transmission of individually identifiable health information. Enforcement actions by the Department of Health and Human Services Office for Civil Rights (OCR) have increased, particularly in relation to compliance with HIPAA security regulations.
Sources:
Nextcure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nextcure Inc’s corporate clients.
For your research, we’ve provided 9 tables on Nextcure Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
